<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fatty acid synthase (FAS) is overexpressed in many human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and is considered to be a promising target for therapy </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the expression of this candidate target in <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, we evaluated expression of FAS protein in 22 cases of esophageal squamous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, 79 cases of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and 16 cases of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>--a lesion thought to represent a pre-invasive precursor to <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Using immunohistochemistry, we found significantly higher levels of FAS expression in 77% of the squamous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, 96% of the <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and 94% of the Barrett's lesions with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, when compared to levels in <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal epithelium and non-dysplastic Barrett mucosa </plain></SENT>
<SENT sid="3" pm="."><plain>To evaluate the potential for inhibiting this enzyme as a treatment of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, we treated mice bearing xenografts of the Colo680N esophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> cell line using C93, a rationally designed molecule that inhibits FAS activity </plain></SENT>
<SENT sid="4" pm="."><plain>In these experiments, C93 significantly inhibited the growth of orthotopic xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> without causing <z:hpo ids='HP_0002039'>anorexia</z:hpo> and <z:hpo ids='HP_0001824'>weight loss</z:hpo> in the treated animals </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that, similar to several other common types of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, FAS is expressed at very high levels in <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> and growth of these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> can be inhibited by pharmacological agents that target this enzyme </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, this high expression of FAS is also seen in high-risk, pre-invasive lesions of the esophagus, leading us to propose considering FAS-inhibitors for purposes of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> chemoprevention </plain></SENT>
</text></document>